Entero Therapeutics, Inc.
ENTO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | 0.01 | 0.02 |
| FCF Yield | -105.94% | -303.87% | -169.11% | -110.12% |
| EV / EBITDA | 260.41 | -0.09 | -0.87 | -0.54 |
| Quality | ||||
| ROIC | -0.03% | -356.02% | -349.66% | -28,282.19% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.51 | 0.78 | 1.53 | 0.55 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 28.42% | 42.37% | 47.56% | -279.55% |
| Safety | ||||
| Net Debt / EBITDA | -0.69 | 0.18 | 0.03 | 0.12 |
| Interest Coverage | 0.00 | -702.08 | -798.42 | -5,256.51 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -6,910.95 | -2,474.55 | -1,821.55 |